Drug Profile


Alternative Names: AFT-801; Alertec; Attenace™; CN 801; CRL 40476; Modasamil; Modasonil; Modavigil; Modiodal; Provigil; Sparlon; Vigil

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cephalon
  • Developer Alfresa Pharma Corporation; Lundbeck A/S; Mitsubishi Tanabe Pharma Corporation; Teva Pharmaceutical Industries
  • Class Benzhydryl compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypersomnia; Narcolepsy
  • No development reported Alzheimer's disease
  • Discontinued Attention-deficit hyperactivity disorder; Parkinson's disease

Most Recent Events

  • 02 Feb 2017 Alfresa Pharma Corporation completes in a long-term phase III trial for Hypersomnia in Japan before February 2017 (JapicCTI-142615)
  • 02 Feb 2017 Alfresa Pharma Corporation initiates enrolment in a long-term phase III trial for Hypersomnia in Japan before February 2017 (JapicCTI-142615)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top